- Home
- FSHP vs MGNX Comparison
FSHP vs MGNX Comparison
Compare FSHP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- MGNX
- Stock Information
- Founded
- FSHP 2018
- MGNX 2000
- Country
- FSHP United States
- MGNX United States
- Employees
- FSHP N/A
- MGNX N/A
- Industry
- FSHP
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- FSHP
- MGNX Health Care
- Exchange
- FSHP NYSE
- MGNX Nasdaq
- Market Cap
- FSHP 92.2M
- MGNX 87.7M
- IPO Year
- FSHP 2024
- MGNX 2013
- Fundamental
- Price
- FSHP $10.42
- MGNX $1.57
- Analyst Decision
- FSHP
- MGNX Hold
- Analyst Count
- FSHP 0
- MGNX 9
- Target Price
- FSHP N/A
- MGNX $5.33
- AVG Volume (30 Days)
- FSHP 173.0
- MGNX 1.9M
- Earning Date
- FSHP 01-01-0001
- MGNX 08-05-2025
- Dividend Yield
- FSHP N/A
- MGNX N/A
- EPS Growth
- FSHP N/A
- MGNX N/A
- EPS
- FSHP 0.21
- MGNX N/A
- Revenue
- FSHP N/A
- MGNX $154,050,000.00
- Revenue This Year
- FSHP N/A
- MGNX N/A
- Revenue Next Year
- FSHP N/A
- MGNX N/A
- P/E Ratio
- FSHP $48.99
- MGNX N/A
- Revenue Growth
- FSHP N/A
- MGNX 255.31
- 52 Week Low
- FSHP $9.99
- MGNX $0.99
- 52 Week High
- FSHP $10.54
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- MGNX 51.47
- Support Level
- FSHP N/A
- MGNX $1.42
- Resistance Level
- FSHP N/A
- MGNX $2.17
- Average True Range (ATR)
- FSHP 0.00
- MGNX 0.17
- MACD
- FSHP 0.00
- MGNX 0.03
- Stochastic Oscillator
- FSHP 0.00
- MGNX 34.48
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.